Chinese surgeons reported the first documented case of a genetically modified pig liver segment transplanted as an auxiliary graft into a human patient with cancer; the xenograft supported metabolic function for 38 days before removal due to thrombotic microangiopathy. The clinical case, published in the Journal of Hepatology, showed immediate graft function — bile production and protein synthesis — and offered a temporary bridge while the native liver regenerated. Investigators treated immune activation complications with immunosuppression and plasma exchange; they stress the case as proof‑of‑concept that xenogeneic organs can function transiently in complex clinical settings. The outcome renews focus on genetic modification, coagulation control, and immunomodulation as the critical technical barriers for broader clinical xenotransplantation.